Fierce Biotech1 min read
saveNovartis CEO argues shareholders ‘happy overall’ with strategy, calls for COINS Act adjustment
Despite a bumpy few months for Novartis that saw a couple of high-profile clinical setbacks, CEO Vas Narasimhan has told Fierce he believes most shareholders remain onside with the company’s strategy.
comments(0)
5-min edit window · permanent after that